NBT Bank N A NY Buys 1,004 Shares of Thermo Fisher Scientific Inc. $TMO

NBT Bank N A NY grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 10,550 shares of the medical research company’s stock after acquiring an additional 1,004 shares during the period. NBT Bank N A NY’s holdings in Thermo Fisher Scientific were worth $4,891,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Elevation Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 35.1% during the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. S.A. Mason LLC raised its stake in shares of Thermo Fisher Scientific by 7.0% in the third quarter. S.A. Mason LLC now owns 319 shares of the medical research company’s stock worth $155,000 after purchasing an additional 21 shares during the last quarter. Lafayette Investments Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.4% during the second quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 22 shares in the last quarter. Finally, Diversified Enterprises LLC boosted its position in shares of Thermo Fisher Scientific by 1.6% during the third quarter. Diversified Enterprises LLC now owns 1,411 shares of the medical research company’s stock valued at $684,000 after buying an additional 22 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on TMO. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, January 7th. Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their target price for the stock from $580.00 to $660.00 in a report on Thursday, December 11th. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Morgan Stanley upped their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $625.47.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 1,058 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the transaction, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. This represents a 36.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 149,271 shares of company stock valued at $86,507,282. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $619.16 on Friday. The stock has a market cap of $232.62 billion, a P/E ratio of 35.77, a P/E/G ratio of 4.11 and a beta of 0.91. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock’s fifty day moving average is $586.34 and its 200 day moving average is $523.82. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $629.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business posted $5.28 earnings per share. The business’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.